source
- nChroma Bio halts sole clinical trial and cuts staff by halfTwo Boston-area biotech founders merged their companies a few years ago to create nChroma Bio, hoping the combined effort would weather a weak market for genetic‑medicine firms. The company has no…
- FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefitThe U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…